NASDAQ:EPRX Eupraxia Pharmaceuticals 8/12/2025 Earnings Report $5.85 -0.15 (-2.50%) Closing price 10/3/2025 03:59 PM EasternExtended Trading$5.84 -0.01 (-0.26%) As of 10/3/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Eupraxia Pharmaceuticals EPS ResultsActual EPS-$0.26Consensus EPS -$0.21Beat/MissMissed by -$0.05One Year Ago EPSN/AEupraxia Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AEupraxia Pharmaceuticals Announcement DetailsQuarterDate8/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsEupraxia Pharmaceuticals' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Eupraxia Pharmaceuticals Earnings HeadlinesEupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for ...September 30, 2025 | finanznachrichten.deEupraxia announces ‘positive’ data from highest-dose cohort in RESOLVE trialSeptember 29, 2025 | msn.comGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter that... Treasury Secretary Bessent could move to officially revalue gold – exactly the scenario I've been warning about as part of the "Mar-a-Lago Accord."October 4 at 2:00 AM | Stansberry Research (Ad)Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI ...September 29, 2025 | finance.yahoo.comEupraxia Pharmaceuticals Closes $80.5 Million Public OfferingSeptember 29, 2025 | tipranks.comEupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development ProgramsSeptember 29, 2025 | globenewswire.comSee More Eupraxia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eupraxia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eupraxia Pharmaceuticals and other key companies, straight to your email. Email Address About Eupraxia PharmaceuticalsEupraxia Pharmaceuticals (NASDAQ:EPRX), Inc. (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus. Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline. The company has established preclinical programs targeting additional autoimmune indications and is preparing to initiate subsequent trials as it builds clinical proof-of-concept for its Treg-focused approach. Eupraxia’s management team comprises seasoned professionals with expertise in immunology, drug development and regulatory affairs. The leadership is committed to leveraging decades of collective experience in biopharma to guide the company’s progression from early-stage research toward potential regulatory milestones and commercial readiness. As a publicly traded company on NASDAQ, Eupraxia Pharmaceuticals aims to deliver innovative, first-in-class treatments that address unmet medical needs in chronic immune-mediated conditions.View Eupraxia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings PepsiCo (10/9/2025)Fastenal (10/13/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
